Degree Name
Master of Science in Nursing (MSN)
Document Type
Major Paper
School
School of Nursing
Department
Nursing
Date of Original Version
12-11-2018
Abstract
Human papillomavirus (HPV) is recognized as the most prevalent sexually transmitted infection in the United States. Prevention of HPV infection is possible with the efficacy of HPV vaccine noted to be nearly 100% when introduced prior to sexual debut. In addition, vaccination post-sexual initiation could have a significant impact on reducing HPV infection and HPV-associated cancers in women. Much focus has been placed on vaccinating adolescents against HPV. However, strategies to increase vaccination rates among females ages 18-26, who remain eligible for vaccination, must be examined. A program evaluation was undertaken to assess the effectiveness of a newly developed pilot program for women ages 19-26 that incorporates assessment of vaccine eligibility during the prenatal period to increase uptake and completion of HPV vaccine postpartum. Data collected from the perinatal vaccination pilot program was performed retrospectively. Through a chart review, postpartum patients age 19-26 were identified and specific areas of focus were examined: whether an HPV dose was administered to vaccine eligible individuals during the inpatient period; whether an additional dose was administered at an ambulatory postpartum visit; and whether a subsequent dose was given at an ambulatory visit if warranted. Data analysis was conducted. Frequencies and percentages in relation to numbers of patients and HPV doses were calculated. Finally, implications for advanced nursing practice were discussed.
Recommended Citation
Maher, Melissa J., "Evaluation of a Perinatal Human Papillomavirus Program" (2018). Master's Theses, Dissertations, Graduate Research and Major Papers Overview. 281.
https://digitalcommons.ric.edu/etd/281
Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-No Derivative Works 4.0 International License.